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Abstract. Sepsis remains the most common cause of death in intensive care units in the USA, with a
current estimate of at least 750,000 cases per year, and 215,000 deaths annually. Despite extensive
research still we do not quite understand the cellular and molecular mechanisms that are involved in
triggering and propagation of septic injury. Endotoxin (lipopolysaccharide from Gram-negative bacteria,
or LPS) has been implicated as a major cause of this syndrome. Inflammatory shock as a consequence of
LPS release remains a serious clinical concern. In humans, inflammatory responses to LPS result in the
release of cytokines and other cell mediators from monocytes and macrophages, which can cause fever,
shock, organ failure and death. A number of different approaches have been investigated to try to treat
and/or prevent the septic shock associated with infections caused by Gram-negative bacteria, including
blockage of one or more of the cytokines induced by LPS. Recently several novel amphipathic
compounds have been developed as direct LPS antagonists at the LPS receptor, TLR4. This review
article will outline the current knowledge on the TLR4-LPS synthesis and discuss the signaling, in vitro
pre-clinical and in vivo clinical evaluation of TLR4 antagonists and their potential use in sepsis and a
variety of diseases such as atherosclerosis as well as hepatic and renal malfunction.
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LPS AND TLR
Bacteria are classified into two groups based on a staining
procedure (1). This staining response is a consequence of the
composition of their membranes. Gram-positive bacteria
present a multi-layered, cross-linked polymer of peptidogly-
can surrounding their plasma membrane, whereas Gram-
negative bacteria have essentially a monolayer (1). The
Gram-negative outer membrane is an asymmetric lipid
bilayer interspersed with proteins. The lipid of this outer
leaflet is almost exclusively constituted by LPS molecules.
Bacterial infection can be life threatening, requiring the
host organism to develop a system to respond to this insult.
The innate immune response is the first line of defense
against infectious agents and is devoted to recognize highly
conserved pathogen motifs in lipopeptides, DNA, dsRNA,
ssRNA, specific proteins and LPS. These motifs are known as
pathogen-associated molecular patterns (PAMPs) (2).
Lipopolysaccharide is composed of three distinct
domains, lipid A, a short core of oligosaccharide and the O-
antigen polysaccharide (Fig. 1). The lipid A domain is the
bioactive component and is recognized during human infec-
tion. The composition of the O-antigen varies between
different Gram-negative bacterial strains. The presence or
absence of O chains determines whether LPS is considered
rough or smooth (3). Full length O chains would render the
LPS smooth while the absence or reduction of O-chains
would make the LPS rough (3,4).
Lipopolysaccharide is a potential drug target since its
presence is critical in membrane stability and also it plays a
prominent role in raising an immune response (2). LPS triggers
the release of many inflammatory cytokines, in particular
TNFα, interleukin-1β and IL-6, and it has been implicated as
the etiological agent of a variety of pathologies ranging from
mild (fever) to lethal (septic shock, organ failure and death)
(5). Thus the structure, function and biosynthesis of LPS have
been areas of intense research in the last decade (6).
The receptors capable of recognizing the pathogen-
associated molecular patterns are Toll-like receptors (TLR)
and scavenger receptors. Ten members of the TLR family
have been identified in humans (7). The Toll was originally
described as a type I transmembrane receptor that controls
the embryonic dorsal-ventral pattern of Drosophila (8). In
fact this pioneering work identified a group of ten different
genes which when deleted produced qualitatively similar
phenotypes. Null mutations on any of these genes lead to a
failure to differentiate patterns on the dorsoventral axis and
resulted on embryonic lethality. The identification of the
sequence of Toll led to the recognition that its carboxyl
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terminal domain was significantly related to that of the
vertebrate interleukin-1 receptor (IL-1R) (8). IL-1R activa-
tion is part of a cascade of events linked to an acute phase
response to infection. This suggested that TLRs could not
only be involved in development but also in the initial
responses to infection in vertebrates. This hypothesis
received further support from the work of Lemaitre et al.,
who found that Toll and other genes from the dorsal group
played a role in innate immune responses to pathogenic fungi
and bacteria (9).
The TLRs belong to a cluster of molecules called the IL-
1R/TLR super-family characterized by the presence of
cytoplasmic Toll/IL-1R (TIR) domains (10). The three
subgroups are: the IL-1R (which present extracellular immu-
noglobulin domains), the adapter subgroup (cytoplasmic
proteins without extracellular region) and the TLRs (9).
TLRs are type I transmembrane proteins with extracellular
amino terminus and a carboxy terminal intracellular domain.
The extracellular domain of the TLR4 contains over 600
amino acids and is highly polymorphic compared with the
transmembrane and cytosolic domains (6). The TIR domain,
composed of three highly conserved regions, contains 150
amino acids and modulates protein-protein interactions
between the TLRs and the adaptor proteins involved in the
signal transduction cascade (10). Unlike other receptors,
TLRs do not have an enzymatic activity (6). Researchers
have identified at least fifteen different negative regulators of
the TLRs, including MyD88s (a short form of MyD88),
IRAKM, suppressor of cell signaling-1 (SOCS1), nucleotide-
binding oligomerization domain 2 (NOD2), phosphatidylino-
sitol-3-kinase (PI3K) and Toll-interacting protein (TOLLIP)
(11). The TLR activation leads to responses that involve the
induction of new genes via transduction pathways such as
NFκB and AP-1 (9). The discovery of TLR lead to the
understanding that an adaptive response mediated by anti-
body responses and T cell activation is tightly coupled to a
second unknown process that requires the presence of
microbial extracts (2,7).
Toll-like receptor 4 (TLR4) is the central signaling
receptor for LPS in mammals (12). The current knowledge
on the structure and function of the TLR4 has opened the
possibility to develop new drug targets to fight sepsis and
other diseases associated with this signaling molecule. TLR4
was identified as the first human homologue of the Drosoph-
ila Toll (13). TLR4 not only engages LPS but it recognizes an
envelope glycoprotein encoded by mouse mammary tumor
virus (MMTV) (14). In addition, TLR4 recognizes ligands
such as heat shock proteins and EDA (extracellular domain
A) in fibronectin (15,16).
TLR4 SIGNALING
TLRs activate a potent immunostimulatory response
which needs to be tightly controlled. TLRs homo o hetero-
dimerize upon ligand binding whereas TLR4 and TLR9
homodimerize (6). TLR signaling involves a family of adaptor
proteins which recruit downstream protein kinases which
activate transcription factors such as nuclear factor-kB (NF-
κB) and members of the interferon (IFN)-regulatory factor
(IRF) family (10). LPS signaling involves the binding of the
LPS-binding protein (LBP) to LPS; this interaction leads to a
disruption of LPS aggregates (10) (Fig. 2 LPS signaling,
modified from (10) with permission). Upon ligand binding
there is the formation of a TLR4 complex with CD14. CD14
was the first molecule shown to enhance LPS signals (17).
Interestingly TLR4 does not require CD14 to trigger epithelial
signaling to uropathogenic E. coli since bladder cells do not
express CD14 (18). In addition a small molecule, myeloid
differentiation 2 receptor (MD-2), participates in this complex
by associating with the TLR4 extracellular domain (19).
MD-2 binds to the LPS monomer and is sensitive to the
acylation pattern of the lipid A moiety. Association of the MD-
2:LPS complex to the ectodomain of the TLR4 finally trans-
duces the signal through the association of intracellular TIR
domain, recruiting the adapter proteins triggering the signaling
cascade (20). In a similar way to TLR2, TLR4 uses the myeloid
differentiation primary-response gene 88 adapter like protein
(MAL) as a bridging adaptor to recruit the myeloid differen-
tiation primary-response gene 88 (MyD88) to activate the NF-
κB, p38 and JNK/MAPK pathways via TRAF6 (9). MAL is
recruited to plasma membrane microdomains containing the
phospholipid PtdIns (4,5)P2 (phosphatidylinositol-4,5-bisphos-
phate). MAL subsequently recruits MyD88 (20). Another
pathway activated by TLR4 involves TRIF-related adaptor
Fig. 1. The structure of LPS.
Fig. 2. LPS signaling [modified from O’Neill and Bowie (10) with
permission]. TLR4 requires four signaling adaptors to function upon
activation by LPS. Similarly to TLR2 it uses MAL to recruit MyD88
and to activate the NFκB pathway and p38 and JNK MAPK
pathways. A second signaling cascade triggered by the LPS-TLR4
interaction involves TRAM. TRAM recruits TRIF which activates
pathways involving TBK1 to IRF3, TRAF6 to NFκB and RIP1 to
apoptosis.
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molecule (TRAM). Similar to MAL, TRAM is also membrane
proximal and requires myristoylation to lodge into the
membrane. TRAM recruits the Toll/interleukin-1 receptor
(TIR)-domain-containing adaptor protein inducing interferon-
β (TRIF) which activates the tumor-necrosis factor-receptor-
associated factor 3 (TRAF3), TRAF6 and receptor interacting
protein 1(RIP1). Recent work with CD14 knockout mice
suggested that TRL4 can function in two ways: one where full
signaling occurs in the presence of CD14 and one limited to
MyD88-dependent signaling (21).
In addition to blocking the intracellular LPS signaling
there are other means to modulate the endotoxin response.
Approaches to alleviate the morbidity and mortality of
patients associated with severe sepsis and septic shock
include: (a) neutralizing LPS or blocking initial LPS-signaling
events by preventing the generation of cell-surface signals, (b)
blocking the intracellular signals induced by endotoxin or the
synthesis of cytokines and other cellular mediators, (c)
inhibiting the release of cytokines (Il-1, IL-6 and IL-8) and
cellular mediators, (d) blocking the TNF-α and IL-1 receptors
to the cellular mediators on their responsive target cell and
(e) inhibiting downstream pathophysiological events such as
acute respiratory distress or aberrant blood clotting (22).
POTENTIAL CLINICAL USES OF TLR4
ANTAGONISTS
TLR mediated innate and/or adaptive immune responses
play an important role in a variety of diseases, including
sepsis, infectious disease, atherosclerosis, kidney failure, liver
disease, pulmonary disease and myocardial ischemia/reperfu-
sion injury (5,23–28). TLRs are expressed in a variety of cell
types including immune and non-immune cells. In addition,
the capability of these receptors to recognize PAMPs is
indicative of their distinct roles in infection, inflammation and
tissue damage (29) (Fig. 3).
TLR4 and Sepsis
According to the definition made by ACCP/SCCM
Consensus Conference in 1992, sepsis is known to be an
early syndrome that may progress to a pathologic state
manifested by hypotension and hypoperfusion known as
septic shock. LPS has been associated with sepsis and the
high mortality rate seen in septic shock (5). However, it is the
exaggerated host response to the systemic release of endo-
toxin that accounts for septic shock from Gram-negative
bacteria (23).
TLR4 up-regulation in non-immune cells after initial
TLR mediated immune response may trigger secondary
responses such as activation of endothelial cells that promotes
the production of adhesion molecules, followed by macro-
phage infiltration and vascular permeability during infection
(30). This cascade may result in a systemic septic syndrome
including tissue perfusions, an imbalanced coagulation cas-
cade and organ failure (31).
TLR4 and Atherosclerosis
Atherosclerosis is an inflammatory disease where acti-
vated cells are involved in its initiation and progression. Guha
and Mackman (32) have shown that activated TLR4 elicits
the production of inflammatory cytokines and chemokines.
Edfeldt et al. (33) have also found that TLR4 is prominently
expressed in endothelial cells of human atherosclerotic lesion,
but poorly expressed in normal human arteries. In the early
atherosclerotic lesion, LPS and other ligands can stimulate
the TLR4 expression on macrophages. The activated recep-
tors can then initiate the signaling cascade that induces the
expression of inflammatory cytokines, proteases, and cyto-
toxic oxygen and nitrogen radicals. These entities further
speed up the progression of the atherosclerotic lesion (34). In
advanced atherosclerotic lesion, LPS can induce the prolifer-
ation of vascular smooth muscle cells, as well as the
expression of elastin-degrading enzyme via TLR4 (35).
Besides that, in response to chemokines, more smooth muscle
cells will also migrate to the sites of the lesions (36). These
predominant changes cause the accumulation of cells, extra-
cellular matrix components, thickening of the intima, as well
as the deformity of the arterial wall.
Furthermore, TLR4 signaling might also be involved in
atherosclerotic plaque destabilization. Grenier and Grignon
have demonstrated that LPS induces the expression of matrix
metalloproteinase-9 (MMP-9) by TLR4 in macrophages;
MMP-9 has been shown to degrade collagen fibrous cap,
thus predisposing plaque to rupture (37).
TLR4 and Liver Injury
In many forms of liver diseases such as alcoholic or non-
alcoholic liver disease, liver failure and inflammation are the
result of a cascade of insults which result in hyper-activation of
inflammatory pathways and liver injury (26,27). Velayudham
and colleagues (26) have shown that there is an up-regulation
of TLR4 receptors in liver granulomas and LPS induced liver
injury. Pathogen-induced TLR4 activation also activates reac-
Fig. 3. TLRs are involved in protective immunity in many infectious
diseases, cancer, allergies and in the pathogenesis of sepsis, autoim-
mune diseases or atherosclerosis. An efficient TLR antagonist may be
of benefit to block or reduce exaggerated TLR stimulation [modified
with permission from Ishii et al. (78)].
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tive oxygen species (ROS), which is a major source of acute
hepatocyte injury and death in the liver. Up-regulation of
peripheral blood monocyte expression of TLR4 also occurs in
patients with chronic hepatitis C (38). In addition, endogenous
gut-derived bacterial LPS have also been implicated as
important cofactors in the pathogenesis of liver injury.
Within the liver, LPS binds to LPS-binding protein
(LBP), which then facilitates its transfer to membrane CD14
on the surface of Kupffer cells in the liver (39). Moreover,
TLR4 can also interact with a protein ligand released from
damaged hepatocytes to extend an existing injury in the liver
(40).
In other studies, there is evidence that high-mobility
group box 1 (HMGB1) can interact with both TLR2 and
TLR4 to induce an inflammatory response during liver
ischemia/reperfusion (IR) injury similar to that initiated by
LPS (41,42). HMGB1 is an intracellular protein present in
many species that functions in regulation and modulation of
gene transcription (42). HMGB1 is released readily from
necrotic or damaged cells, which may signal through TLR4
the presence of advancing tissue injury, initiating an inflam-
matory response that further damages viable cells (42).
TLR4 and Ischemia/Reperfusion Injury
The restoration of blood flow to the ischemic heart has
often caused myocardial ischemic/reperfusion (MI/R) injury.
An inflammatory response triggered by MI/R injury can
irreversibly cause damage to the viable tissue surrounding the
infarct, thereby further extending the injury. It is still unclear
how innate immune signaling pathways are initiated during
MI/R injury (43). However, TLR4, which is also present in
cardiomyocytes, has been thought to play a role in mediating
MI/R injury. Schuster and Nelson (28) have shown that TLR4
receptor is up-regulated in response to myocardial injury.
Furthermore, Shimamoto and colleagues have shown that
TLR4 activates NF-κB-dependent transcription of inflamma-
tory cytokine genes in MI/R injury. The TLR4-mediated
injury appears to occur through activation of c-Jun NH2-
terminal kinase (JNK) and translocation of NF-κB (41). It is
also believed that TLR4 recognizes endogenous molecules
that are exposed during cellular injury and extracellular
matrix remodeling, independent of pathogen invasion (44).
Thus, inhibition of TLR4 signaling pathway may be a
potential therapeutic target to treat the myocardium damage
in the ischemia/reperfusion setting.
TLR4 and Kidney Disease
Acute renal failure (ARF) occurs in close to 5% of
hospital admissions, and is a leading cause of morbidity and
mortality. A common cause of ARF is sepsis, which results
from overwhelming infection (25). Cunningham and col-
leagues (25) have shown that LPS insult leads to renal cell
apoptosis and renal neutrophil infiltration.
Tubular epithelial cells of the kidney are among the non-
immune cells that express TLR1, TLR1-2, TLR1-3, TLR1-4,
and TLR1-6, suggesting that these TLR might contribute to
the activation of immune responses in tubulointerstitial injury
(45). In addition, receptors such as TLR4, TLR2, CD91 and
the receptor for the advanced glycation end-products
(RAGE), allow leukocytes and renal cells to recognize
molecules released by injured cells. These receptors are
sentinels for tissue necrosis (46). Upon stimulation with LPS
in renal infection or other endogenous ligands from necrotic
tubular cells, the activated TLR4 has been shown to
specifically stimulate the NF-κB pathway in response to
oxidative stress (47). Furthermore, TLR4 activation on
tubular epithelial cells and circulating immune cells leads to
secretion of cytokines and chemokines that either directly or
indirectly contributes to renal injury.
TLR4 in Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a medical condition
that predominantly affects the gastrointestinal tract (48). De
Jager et al. showed that TLR4 and its signaling molecule
TIRAP affect susceptibility to IBD (49). Recent studies have
shown that TLR4−/− and MyD88−/− knockout mice tend to be
more prone to severe dextran sulfate sodium-induced colitis
than their wild-type littermates (50). Interestingly, CRX-526 a
TLR4 antagonist has been shown to prevent an inflammatory
disease in the dextran sulfate sodium and mdr1a−/−/1b−/−
deficient mice models (51). To explain these contradictory
results we have to consider that constitutive signaling through
TLR4 may result in the production of tissue protective factors
such as IL-6 and TNF-α (49). This is the scenario in the
MyD88−/− knockout mice, while in the case of the CRX-526
we may have selective downregulation of one of the TLR-4/
LPS signaling pathways.
TLR4 and Pulmonary Disease
Simpson and colleagues observed an increased expres-
sion of TLR2, TLR4 and CD14, as well as the pro-
inflammatory cytokines IL-8 and IL-1β in neutrophilic
asthma and bronchiectasis patients compared to controls.
These groups also had higher airway endotoxin levels than
the control group (23). In another study, there was also an
increased pulmonary expression of inflammatory cytokines
occurring in the lung during experimental endotoxemia. The
cytokine production further contributes to acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS)
(52,53). Baumgarten and colleagues showed that LPS induces
pro-inflammatory cytokines in the lung via the TLR4/CD14
signaling cascade, suggesting a role of the innate immune
response in the pathogenesis of ALI/ARDS (52).
SYNTHESIS OF NOVEL ANALOGUES
LPS biosynthesis occurs by two distinct, yet convergent
pathways: one for the lipid A core and another for the
polysaccharide O antigen. After independent synthesis, the
two parts are ligated together to complete the LPS molecule
(4). Amongst the most important TLR4 antagonists devel-
oped so far we have CRX-526, E5531 and E5564.
CRX-526
Aminoalkyl glucosaminide 4-phosphates or AGPs are a
class of lipid A mimetics in which the reducing sugar of lipid
A has been replaced with an N-acylated aminoalkyl aglycon
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unit (54). The AGPs contain an L-serine-based aglycon unit
as well as three (R)-3-n-alkanoyloxytetradecanoyl residues
comprised of even-numbered normal fatty acyl chains be-
tween 6 and 14 carbon atoms in length. All members of this
family have 14 carbon atoms in the “primary” fatty acid,
which is the -hydroxy fatty acid attached directly to the AGP
backbone. -Hydroxymyristic acid is the most common of the
primary fatty acids present in lipid A. These compounds were
used in a variety of cell-based and an in vivo model to
determine structure-activity relationships related to AGP acyl
chain length and stimulation via TLR4 (54). Figure 4 shows
the chemical structure of two AGPs: MPL and CRX-526. The
structure of CRX-526 differs significantly from monophos-
phoryl lipid A (MPL) and other TLR4-agonist AGP in the
length of its secondary fatty acyl chains (SAC): for instance
CRX-526 contains 3 SAC of 6 carbons in length, whereas
MPL and other AGP, which signal through the TLR4
complex, contain SAC of >10 carbons in length (55).
The synthesis of AGPs has been described elsewhere
(55). Briefly, the AGPs were prepared by a highly convergent
method, which allowed chemical differentiation of the
hydroxyl and amino groups and sequential introduction of
the (R)-3-n-alkanoyloxytetrahexanoyl residues. The AGPs
were purified by flash chromatography on silica gel (to >95%
purity) and analyzed as a triethylammonium salt by standard
analytical methods. For stimulation in vitro, the AGPs were
formulated in water containing 216 μg/ml dipalmitoylphos-
phatidyl choline [aqueous formulation (AF)], 0.2% trietha-




mino]-O-phosphono-D-glucopyranose tetrasodium salt) and




phosphate), tetrasodium salt], formula weight 1401.60) (mo-
lecular formula: C66H122N2Na4O19P2) were synthesized by
Eisai Research Institute of Boston (Andover, MA, USA)
(53). The structure of E5531, an analog of the lipid A of
Rhodobacter capsulatus, is presented elsewhere (56). The
structure of E5564 is depicted in Fig. 5. The crystal structure
of the TLR4-MD2 complex with bound E5564 was recently
published (57) suggesting that the mechanism of action of
E5564 is binding through a large internal pocket in MD-2.
PRE-CLINICAL EVALUATION
An important consideration in the development of assays
is to determine the efficacy and toxicity of the compounds
and the potency required to obtain a biological effect. A high
potency is a key factor that would limit the high cost of
synthesis and purification of such a compound. To illustrate
the challenges in developing a synthetic endotoxin receptor
antagonist we present the case of E5564.
In vitro, E5564 dose-dependently inhibited LPS-mediated
activation of primary cultures of human myeloid cells and
mouse tissue culture macrophage cell lines as well as human or
animal whole blood at nanomolar concentrations as measured
by production of tumor TNF- and other cytokines. E5564 also
blocked the ability of Gram negative bacteria to stimulate
human cytokine production in whole blood. In vivo, E5564
blocked induction of LPS-induced cytokines and LPS or
bacterial-induced lethality in primed mice. E5564 was devoid
of agonistic activity when tested both in vitro and in vivo and
had no antagonistic activity against Gram positive-mediated
cellular activation at concentrations up to 1 μM. E5564 blocked
LPS-mediated activation of nuclear factor-B in TLR4/MD-2-
transfected cells. In a mouse macrophage cell line, activity of
E5564 was independent of serum, suggesting that E5564 exerts
its activity through the cell surface receptor(s) for LPS, without
the need for serum LPS transfer proteins. Similar to E5531,
another lipid A-like antagonist, E5564 associates with plasma
lipoproteins, causing low concentrations of E5564 to be
quantitatively inactivated in a dose- and time-dependent
manner. However, compared with E5531, E5564 is a more
potent inhibitor of cytokine generation, and higher doses
retain activity for a period of time likely sufficient to permit
clinical application. These results indicate that E5564 is a
potent LPS antagonist and lacks agonistic activity in human
and animal model systems, making it a potentially effective
therapeutic agent for treatment of disease states caused by
LPS.
Fig. 4. The chemical structures of MPL and CRX-526 [modified from
(51) with permission].
Fig. 5. The chemical structure of E5564.
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Compared with E5531, E5564 is structurally and syn-
thetically less complex, yet seems to possess superior activity
and pharmacological characteristics. Although E5531 demon-
strated potent inhibition of LPS when added to blood in vitro
and in vivo, activity decreased as a function of time. This
reaction has been shown to be due to interaction of E5531
with plasma lipoproteins (58–60). E5564 is an inhibitor of
LPS-mediated stimulation of responsive cells in vitro and in
vivo as measured by production of cytokines, as well as
morbidity and mortality associated with LPS poisoning in
animal models. Because E5564 is a structural analog of the
lipid A portion of LPS, it is logical to hypothesize that the
antagonist interacts with the same signaling components that
bind to LPS such as the soluble serum proteins LBP and
sCD14, as well as membrane-associated CD14 and perhaps
the TLR4/MD-2 receptor complex. E5564 blocked LPS/
sCD14-induced reporter activity in TLR4/MD-2-expressing
HEK293 (61), but not TLR2-mediated signaling by heat-
killed S. aureus. These findings indicate that E5564 selectively
inhibits LPS signaling via TLR4/MD-2. However, a limitation
to this model system is that LPS requires the presence of
sCD14 for cellular activation, making it difficult to determine
whether E5564 blocks LPS binding to sCD14 or TLR4/MD-2.
Results from experiments indicated that serum components
did not affect the potency of E5564, indicating that they are
not critical to E5564 antagonistic activity (61).
Further support of the hypothesis that interaction of
E5564 at CD14 does not play a key role in its activity comes
from a previous study by Lien et al. describing the activity of
novel synthetic acyclic lipid A-like agonists that activate
TLR4/MD-2 in the absence of CD14 (62). E5564 inhibited
the actions of these agonists under serum-free conditions.
Taken together, these lines of evidence make it tempting to
speculate that E5564 binds to TLR4/MD-2 complex, thereby
blocking LPS binding or transmembrane signaling. The
downstream effect of inhibiting the initial signaling by LPS
seems to be an inhibition of all LPS-induced cytokines
measured, including TNF-, IL-1, IL-6, IL-8, IL-10, and nitric
oxide, which was measured in cultured cells, whole blood, and
in vivo. Recently the crystal structure of the TLR4/MD-2 and
E5564 has been described confirming the physical interaction
of these molecules (57).
Comparisons of antagonistic potency in cells cultured in
10% serum versus whole blood allow us to determine whether
the high concentration of proteins/lipoproteins present in
serum inhibit E5564 activity. In all systems but the rat,
antagonistic activity of E5564 in cultured cells was within
fourfold that measured in high serum (blood) compared with
assays done in low-serum conditions (cultured cells or mono-
cytes) (60,63). This indicates that serum has little or no
inhibitory effect on antagonistic activity under these in vitro
conditions. However, extended incubations in whole blood
demonstrated that activity of E5564 was measurably reduced.
Other studies indicate that like E5531, E5564 is not rapidly
metabolized, but binds to lipoproteins, and time dependently
loses antagonistic activity (64). The observation that lipopro-
teins reduce drug activity may explain the poor activity of
E5564 in rat blood that has relatively high lipoprotein content.
During extended incubation in whole blood, E5564
retained activity better than similar concentrations of the
first-generation antagonist E5531. Based on the proposed
mechanism of action as a cell surface antagonist, it is likely
that E5564 can completely block cellular activation by LPS.
This block is achieved by concentrations of E5564 as low as
10 nM (14 ng/ml) in vitro, and at doses of 1 mg/kg or less in
animal models challenged with lethal LPS doses.
Both LPS-challenge model and infection model use
animals that have been sensitized or primed to LPS by previous
infection with BCG, increasing cytokine response and lowering
the threshold lethal dose of endotoxin (61). All animal models
of sepsis and infection have been criticized for their inability to
closely mimic human sepsis. The primed model is the most
relevant to the study of endotoxin antagonists such as E5564. It
is well known that compared with humans, unprimed rodents
such as rats and mice and primates demonstrate a profound
insensitivity to endotoxin, requiring endotoxin doses as high as
milligrams per kilogram, whereas humans demonstrate repro-
ducible response to endotoxin at doses as low as 2 ng/kg. This
argues that either LPS contributes only weakly to the
inflammatory process in animal models, or that response to
infection occurs only after the level of infection is very high,
representing a process different from that in more LPS-
sensitive species such as humans (61).
Even in primed animal models, lethal doses of LPS are
high, approximately 100 μg/kg, generating estimated plasma
concentrations of ∼1 μg/ml. These plasma levels are still
>100-fold that found in even the most extreme cases of
human sepsis (65). Because the dose of E5564 required to
protect against LPS is proportional to the LPS challenge
dose, studying E5564 in these animal models indicates that
E5564 can be a safe and effective antagonist even under these
extraordinary conditions. E5564 is approximately tenfold
better in human blood than mouse blood (IC50=1.6 nM in
human whole blood; Table I versus ∼20 nM in mouse whole
blood; Table II).
Complete block of cytokine response by 10 nM E5564 in
blood extrapolates to a human dose of approximately 100 μg in
a 70-kg individual. Recent studies have supported this extrap-
olation by finding that a dose of 100 μg of E5564 given to normal
volunteers over 30 min completely blocks response (signs,
symptoms, and cytokines) to a dose of 4 ng/kg endotoxin
administered at the midpoint of the E5564 infusion (66).
In vitro and ex vivo assays have found that low
concentrations of E5564 time dependently lose ability to
inhibit LPS response. In light of these observations, it is
perhaps not surprising that low doses of E5564 demonstrate a
time-dependent loss of activity after administration into
normal volunteers. This loss in activity is overcome when
E5564 doses are increased (67). Phase I clinical safety and
tolerability assays indicate that E5564 is safe and except for
the occurrence of phlebitis, well tolerated at doses up to
252 mg administered over 72 h. At this dose, in vivo
antagonistic activity is retained for at least an additional
72 h after discontinuing infusion. This leads us to believe that
sufficient therapeutic activity can readily be administered to
patients (67). The safety and efficacy of E5564 are currently
been analyzed in a phase III randomized controlled study.
TAK-242
TAK-242 has been demonstrated to suppress LPS-
induced inflammation (68,69). Recently, TAK-242 has been
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shown to almost completely suppress production of nitric oxide
or TNFα induced by LPS in mouse RAW264.7, human U937
and P31/FUJ cells (70). In a HEK293 cell model where TLR4,
MD-2 and CD14 were co-expressed, this antagonist showed
specificity to TLR4 as other TLRs, TLR1/2, TLR2/6, TLR3,
TLR5, TLR7 and TLT9 were not affected by this drug (70).
CLINICAL EVALUATION
Sepsis is a major cause of high mortality rate in intensive
care units in the USA (71). Severe sepsis usually leads to organ
failure. Currently, over 30 pharmaceutical products have been
in the development stage to treat this condition, yet only few
have reached the market (72). Many of these target specific
inflammatory mediators have been unsuccessful because of the
complex nature of sepsis. For the treatment of sepsis, there are
a few products that are being investigated in clinical studies via
blocking different mechanisms of the body’s innate immune
system. Eli Lilly’s Xigris® was one of the few drugs currently
available on the market to treat sepsis. Xigris® is a recombi-
nant human activated protein C that has anti-inflammatory,
anti-thrombotic and pro-fibrinolytic properties to block the
coagulation cascade which plays a critical role in the develop-
ment of organ failure due to sepsis (73). In addition,
simvastatin and atorvastatin had also shown to have some
non-specific anti-inflammatory effects contributing to their
clinical benefits in treating sepsis (63). However, statins are
currently not been considered as a treatment for sepsis. To find
a more specific target, scientists have identified TLR4 as one of
the candidates in blocking the innate immune system. Only
two TLR4 antagonists, E5564 and TAK-242, have made far
into the clinical phase (Table III).
E5564
In Wong, et al., determined the safety and tolerability of
E5564 following a 30-min intravenous infusion in healthy
male volunteers (74). This was a single-center, randomized,
double-blind, placebo-controlled, sequential-group, single-
dose study of E5564. The drug dose levels used were 350,
1,000, 2,000 or 3,500 μg. All doses of E5564 presented a long
pharmacokinetic half-life and short in vivo pharmacodynamic
half life which generally less than several hours when it is co-
administered with LPS in healthy volunteers (74). The Cmax
and AUC (area under the curve) of E5564 increased in a
dose-dependent manner. E5564 pharmacokinetics was char-
acterized by a slow clearance (0.67–0.95 ml h−1 kg−1), a small
volume of distribution (41–54 ml/kg), and a relatively long
elimination half life (42–51 h) in healthy male volunteers.
Thus, to overcome this low PD, the doses of E5564 given to
the volunteers needed to be adjusted. In summary, all doses
were demonstrated to be safe and well tolerated. Safety and





TNF-Induced (pg/ml) E5564 IC50 (nM) IL-6-Induced (ng/ml) E5564 IC50 (nM)
Mouse peritoneal macrophages 3,315±318 20.4±12.5 5.0±0.53 16.6±6.7
Mouse blood NT NT 13.0±0.18 20.2±7.0
Rat peritoneal macrophages 2,867±326 7±5.6 93±99 16.2±17.5
(range 23–163) (range 3.9–28.6)
Rat blood 2,241±335 136±61 55.8±12 ∼2,400
Guinea pig macrophages 1,897±348 0.3±0.15 3.0±0.43 0.5±0.3
Cells or blood prepared as described under “Materials and Methods” (61) were stimulated with 10 ng/ml LPS plus a range of doses of E5564
for 2 or 3 h. Supernatant or plasma samples were assayed for the indicated cytokines. Most values were determined from triplicate incubations
done three times, except rat peritoneal macrophages (n=2). Basal induction of cytokine (cytokine values measured after incubation in the
absence of LPS) was 4% or less of values from the LPS-stimulated samples in all cases
NT Not tested
Table I. E5564 Inhibition of TNF- Induced by LPS from Various












K. pneumoniae 10 2,868±104 8.5±5.0
P. aeruginosa 10 2,027±185 1.0±0.21
S. Minnesota 10 2,793±99 12.4±5.1
S. enteritidis 1 2,279±184 2.6±0.47
S. typhimurium 10 3,091±182 9.4±6.7
S. marcescens 10 3,128±91 10.3±6.2
S. minnesota R595 10 1,578±284 7.6±2.9
E. coli 10 1,142±155 1.6±0.3
Whole bacteriac




Whole E. coli 100 3,172±413 0.65±0.32
Lipid A
E. coli 10 2,500±294 1.2±0.7
aEach value represents the mean and standard error of triplicate
determinations obtained from three experiments.
cNanograms per milliliter of whole bacteria from lyophilized powder.
bLPS from V. cholerae Inaba 569B and B. pertussis 165 were also
analyzed; however, they were only weakly active at stimulating
release of TNF- from whole blood and stimulation was highly
variable. E5564 inhibited this weak stimulation with IC50 values of
1 nM or less for both strains.
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tolerability assessments included monitoring and questioning
of the subjects about adverse events, physical examinations,
clinical laboratory tests (including hematology, blood
chemistry, and urinalysis), and vital sign measurements
(including supine and standing pulse rate and blood
pressure), and 12-lead electrocardiograms (ECGs) and
cytokine concentration testing. In this study, E5564 inhibited
LPS-induced tumor necrosis factor-α in a dose-dependent
manner, and at the higher doses (2 and 3.5 mg), antagonistic
activity was measurable up to 8 h post-infusion. E5564 lacked
LPS-like agonist activity at doses up to 3.5 mg (74).
In another study of healthy volunteers with experimental
endotoxemia, Lynn et al. (66) found phlebitis was only
associated with 72 h continuous intravenous infusion of E5564
but not with four hour infusion of E5564 into a peripheral vein.
In this study the authors explored the possibility of extended
pharmacokinetic activity of E5564. The infusion period was
changed from bulk dosing to a 4- and 72-h infusions of E5564
into normal volunteers. They observed that at 4 h infusion of
E5564, 3 mg/h completely blocked endotoxin administered 8 h
post-dosing. Additionally, they observed that administration of
3.4 mg of E5564/hX72 h completely blocked the effects of
endotoxin challenge at the end of dosing (72 h), and at 48 and
72 h post dosing. A lower dose of E5564 of 2 mg was also
studied, and they found that 0.5 mg/h×4 h, ameliorated but did
not block most effects of endotoxin 8 h post-dosing. This work
also studied the effect of varying plasma lipoprotein content on
E5564 activity in subjects who have high or low cholesterol
levels (>180 or <140 mg/dl) after a 72 h infusion of 252 mg of
E5564. The distribution of E5564 into the lipoprotein fractions
was not significantly different between the low- and high-
cholesterol groups (66).
In another study by Rossignol et al., a 72 h intravenous
infusion and higher doses (500, 2,000 or 3,500 μg/h) of E5564
were administered into healthy volunteers (67). E5564 has a
slow plasma clearance (0.679 to 0.930 ml h−1 kg−1 of body
weight), a small volume of distribution (45.6 to 49.8 ml/kg), and
a relatively long half-life (50.4 to 62.7 h). All these
pharmacokinetic parameters obtained are comparable to the
study done by Wong et al. (74). The association of E5564 with
plasma lipoproteins was also investigated and it was found that
the majority (∼55%) of the drug was bound specifically to
high-density lipoprotein (HDL), but not low-density
lipoproteins, very-low-density lipoproteins, or albumin (67).
A Phase II multi-site, double-blind, randomized, ascending-
dose, placebo-controlled safety study on E5564 was conducted in
cardiac surgery patients (75). Patients undergoing coronary
artery bypass graft and/or cardiac valvular surgery with
cardiopulmonary bypass were enrolled. Patients received a four
hour infusion of 2, 12 or 28 mg of E5564 before cardiopulmo-
nary bypass. No significant safety concerns were identified. No
significant difference was observed in most variables related to
systemic inflammation or organ dysfunction/injury. This phase
II safety study suggests that the administration of E5564 is not
associated with toxicity in cardiac surgical patients. However,
the relatively small sample size used in this study limits the
conclusion regarding rare adverse events or the potential
clinical benefits of this drug (75).
The potential of E5564 as a sepsis treatment was
addressed by Kaneko et al. (76), Surface Plasmon resonance
(SPR) analysis indicated that E5564 binds to LPS binding
protein (LBP), in a manner similar to LPS. Blood withdrawn
from healthy volunteers was treated with heparin to prevent
clotting. At doses of E5564 relevant to its clinical use (i.e.
6 μg/ml), antibodies against LBP did not influence either the
distribution of E5564 to non-HDL lipoprotein fractions or the
transfer of E5564 from non-HDLs to HDL. LBP binds E5564
in a manner similar to LPS, but does not play a role in E5564
redistribution/binding to lipoprotein and plasma clearance.
Czeslick et al. (77) carried out an ex vivo study on the
effect of E5564 on production of LPS-induced pro-inflamma-
tory cytokines, particularly IL-6 and TNF-α, in LPS-induced
human monocytes. In this study, they recruited 10 healthy
volunteers and obtained their whole blood samples and pre-
incubated with 0.001, 0.003, 0.01, 0.03, 0.1, 1 and 10 ng/ml
E5564 for 45 min and after stimulated with 0.2 ng/ml of LPS.
They found that E5564 (0.003 up to 10 ng/ml) caused a dose-
dependent inhibitory effect on IL-6 and TNF-α production in
LPS-stimulated human monocytes. They concluded that
E5564 has a significant LPS inhibitory effect via down
regulation of the intracellular generation of pro-inflammatory
cytokines IL-6 and TNF-α in human monocytes (77).
The association of E5564 with plasma protein and
lipoprotein was studied in plasma obtained from fasted human
subjects with various lipid concentrations (64). It was reported
that the majority of E5564 was recovered in the high-density
lipoprotein (HDL) fraction. Additionally, they had shown
increasing levels of TG-rich lipoprotein (TRL) lipid (TC and
TG) concentrations resulted in a significant increase in the
percentage of E5564 recovered in the TRL fraction. Further-
more, their findings had suggested that E5564 does not
influence CETP-mediated transfer activity (64).
TAK-242
Human peripheral blood mononuclear cells (PBMCs)
were isolated from peripheral blood obtained from healthy
human volunteers by density gradient centrifugation (68).
TAK-242 was effective in human cells and inhibited the
production of TNF-α, IL-6, and IL-1b from PBMCs stimulat-
ed with LPS and IFN-gamma, with IC50 values of TAK-242
ranging from 5.3 to 58 nM. There were four donors used for
Table III. Clinical Development of Two TLR4 Antagonists (59,68)
Compound Status Studied population Timeline Company Indication
E5564 III Global 2006– Eisai Septic shock
(Eritoran) II North America 2002–2005 Eisai Septic shock
I North America 1999–2001 Eisai Septic shock
TAK-242 III Japan, US Europe 2005–2008 Takeda Severe sepsis
I Japan, US Europe 2005 Takeda Severe sepsis
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this study. There was no marked difference in the IC50 values
of TAK-242 amongst them. TAK-242 showed suppressive
effects on the production of various inflammatory mediators
from human monocytes and macrophages stimulated with
LPS. TAK-242 also suppressed the production of these
cytokines from LPS-stimulated human peripheral blood
mononuclear cells (PBMCs) at IC50 values from 11 to 33
nM. In addition, the inhibitory effects on the LPS-induced IL-
6 and IL-12 production were similar in human PBMCs,
monocytes, and macrophages. TAK-242 suppressed the
cytokine production induced by Toll-like receptor (TLR) 4
ligands, but not by ligands for TLR2, TLR3, and TLR9. TAK-
242 suppresses the production of multiple cytokines by
selectively inhibiting TLR4 intracellular signaling (68).
CONCLUSIONS
The manipulation or intervention of TLR-mediated
immune responses is a potential approach to treat and
prevent the septic shock and variety of associated diseases.
However, blocking TLR may lead to ‘inappropriate’ immune
responses such allergic Th2 responses, or immunological
tolerance (78). Thus, it seems clear that the risks and benefits
of manipulation of TLR mediated immune responses need to
be balanced and require further investigation.
REFERENCES
1. T. J. Beveridge. Use of the gram stain in microbiology. Biotech.
Histochem. 76:111–118 (2001).
2. C. A. Janeway Jr, and R. Medzhitov. Innate immune recognition.
Annu. Rev. Immunol. 20:197–216 (2002).
3. J. C. Chow, D. W. Young, D. T. Golenbock, W. J. Christ, and F.
Gusovsky. Toll-like receptor-4 mediates lipopolysaccharide-
induced signal transduction. J. Biol. Chem. 274:10689–10692
(1999).
4. J. A. Yethon, and C. Whitfield. Lipopolysaccharide as a target
for the development of novel therapeutics in gram-negative
bacteria. Curr. Drug Targets Infect. Disord. 1:91–106 (2001).
5. J. E. Parrillo, M. M. Parker, C. Natanson, A. F. Suffredini, R. L.
Danner, R. E. Cunnion, and F. P. Ognibene. Septic shock in
humans. Advances in the understanding of pathogenesis, cardio-
vascular dysfunction, and therapy. Ann. Intern. Med. 113:227–242
(1990).
6. N. J. Gay, and M. Gangloff. Structure and function of toll
receptors and their ligands. Annu. Rev. Biochem. 76:141–165
(2007).
7. T. K. Means, D. T. Golenbock, and M. J. Fenton. Structure and
function of Toll-like receptor proteins. Life Sci. 68:241–258
(2000).
8. C. Hashimoto, K. L. Hudson, and K. V. Anderson. The Toll gene
of Drosophila, required for dorsal-ventral embryonic polarity,
appears to encode a transmembrane protein. Cell. 52:269–279
(1988).
9. S. L. Doyle, and L. A. O’Neill. Toll-like receptors: from the
discovery of NFkappaB to new insights into transcriptional
regulations in innate immunity. Biochem. Pharmacol. 72:1102–
1113 (2006).
10. L. A. O’Neill, and A. G. Bowie. The family of five: TIR-domain-
containing adaptors in Toll-like receptor signalling. Nat. Rev.
Immunol. 7:353–364 (2007).
11. F. Y. Liew, D. Xu, E. K. Brint, and L. A. O’Neill. Negative
regulation of toll-like receptor-mediated immune responses. Nat.
Rev. Immunol. 5:446–458 (2005).
12. L. L. Stoll, G. M. Denning, and N. L. Weintraub. Endotoxin,
TLR4 signaling and vascular inflammation: potential therapeutic
targets in cardiovascular disease. Curr. Pharm. Des. 12:4229–4245
(2006).
13. R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr. A
human homologue of the Drosophila Toll protein signals
activation of adaptive immunity. Nature. 388:394–397 (1997).
14. B. A. Jude, Y. Pobezinskaya, J. Bishop, S. Parke, R. M.
Medzhitov, A. V. Chervonsky, and T. V. Golovkina. Subversion
of the innate immune system by a retrovirus. Nat. Immunol.
4:573–578 (2003).
15. Y. Okamura, M. Watari, E. S. Jerud, D. W. Young, S. T. Ishizaka,
J. Rose, J. C. Chow, and J. F. Strauss 3rd. The extra domain A of
fibronectin activates Toll-like receptor 4. J. Biol. Chem.
276:10229–10233 (2001).
16. S. P. Gondokaryono, H. Ushio, F. Niyonsaba, M. Hara, H.
Takenaka, S. T. Jayawardana, S. Ikeda, K. Okumura, and H.
Ogawa. The extra domain A of fibronectin stimulates murine
mast cells via toll-like receptor 4. J. Leukoc. Biol. 82:657–665
(2007).
17. S. D. Wright, R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C.
Mathison. CD14, a receptor for complexes of lipopolysaccharide
(LPS) and LPS binding protein. Science. 249:1431–1433 (1990).
18. J. C. Sirard, M. Bayardo, and A. Didierlaurent. Pathogen-
specific TLR signaling in mucosa: mutual contribution of
microbial TLR agonists and virulence factors. Eur. J. Immunol.
36:260–263 (2006).
19. R. Shimazu, S. Akashi, H. Ogata, Y. Nagai, K. Fukudome, K.
Miyake, and M. Kimoto. MD-2, a molecule that confers
lipopolysaccharide responsiveness on Toll-like receptor 4. J.
Exp. Med. 189:1777–1782 (1999).
20. R. Jerala. Structural biology of the LPS recognition. Int. J. Med.
Microbiol. 297:353–363 (2007).
21. Z. Jiang, P. Georgel, X. Du, L. Shamel, S. Sovath, S. Mudd, M.
Huber, C. Kalis, S. Keck, C. Galanos, M. Freudenberg, and B.
Beutler. CD14 is required for MyD88-independent LPS signaling.
Nat. Immunol. 6:565–570 (2005).
22. L. D. Hawkins, W. J. Christ, and D. P. Rossignol. Inhibition of
endotoxin response by synthetic TLR4 antagonists. Curr. Top
Med. Chem. 4:1147–1171 (2004).
23. J. L. Simpson, T. V. Grissell, J. Douwes, R. J. Scott, M. J. Boyle,
and P. G. Gibson. Innate immune activation in neutrophilic
asthma and bronchiectasis. Thorax. 62:211–218 (2007).
24. K. S. Michelsen, T. M. Doherty, P. K. Shah, and M. Arditi. Role
of Toll-like receptors in atherosclerosis. Circ. Res. 95:e96–e97
(2004).
25. P. N. Cunningham, Y. Wang, R. Guo, G. He, and R. J. Quigg.
Role of Toll-like receptor 4 in endotoxin-induced acute renal
failure. J. Immunol. 172:2629–2635 (2004).
26. A. Velayudham, I. Hritz, A. Dolganiuc, P. Mandrekar, E. Kurt-
Jones, and G. Szabo. Critical role of toll-like receptors and the
common TLR adaptor, MyD88, in induction of granulomas and
liver injury. J. Hepatol. 45:813–824 (2006).
27. A. M. Diehl. Cytokine regulation of liver injury and repair.
Immunol. Rev. 174:160–171 (2000).
28. J. M. Schuster, and P. S. Nelson. Toll receptors: an expanding
role in our understanding of human disease. J. Leukoc. Biol.
67:767–773 (2000).
29. H. Li, Y. He, J. Zhang, S. Sun, and B. Sun. Lipopolysaccharide
regulates toll-like receptor 4 expression in human aortic smooth
muscle cells. Cell Biol. Int. 31:831–835 (2007).
30. H. Bosshart, and M. Heinzelmann. Targeting bacterial endotox-
in: two sides of a coin. Ann. N. Y. Acad. Sci. 1096:1–17 (2007).
31. M. Wendel, R. Paul, and A. R. Heller. Lipoproteins in
inflammation and sepsis. II. Clinical aspects. Intensive. Care
Med. 33:25–35 (2007).
32. M. Guha, and N. Mackman. LPS induction of gene expression in
human monocytes. Cell Signal. 13:85–94 (2001).
33. K. Edfeldt, J. Swedenborg, G. K. Hansson, and Z. Q. Yan.
Expression of toll-like receptors in human atherosclerotic
lesions: a possible pathway for plaque activation. Circulation.
105:1158–1161 (2002).
34. S. T. Smiley, J. A. King, and W. W. Hancock. Fibrinogen
stimulates macrophage chemokine secretion through toll-like
receptor 4. J. Immunol. 167:2887–2894 (2001).
1759Discovery and Development of TLR4 Antagonists
35. M. Watari, H. Watari, I. Nachamkin, and J. F. Strauss.
Lipopolysaccharide induces expression of genes encoding pro-
inflammatory cytokines and the elastin-degrading enzyme,
cathepsin S, in human cervical smooth-muscle cells. J. Soc.
Gynecol. Investig. 7:190–198 (2000).
36. S. Sasu, D. LaVerda, N. Qureshi, D. T. Golenbock, and D.
Beasley. Chlamydia pneumoniae and chlamydial heat shock
protein 60 stimulate proliferation of human vascular smooth
muscle cells via toll-like receptor 4 and p44/p42 mitogen-
activated protein kinase activation. Circ. Res. 89:244–250 (2001).
37. D. Grenier, and L. Grignon. Response of human macrophage-like
cells to stimulation by Fusobacterium nucleatum ssp. nucleatum
lipopolysaccharide. Oral Microbiol Immunol. 21:190–196 (2006).
38. S. M. Riordan, N. A. Skinner, J. Kurtovic, S. Locarnini, C. J. McIver,
R. Williams, and K. Visvanathan. Toll-like receptor expression in
chronic hepatitis C: correlation with pro-inflammatory cytokine
levels and liver injury. Inflamm. Res. 55:279–285 (2006).
39. G. L. Su. Lipopolysaccharides in liver injury: molecular mecha-
nisms of Kupffer cell activation. Am. J. Physiol. Gastrointest.
Liver Physiol. 283:G256–G265 (2002).
40. A. Tsung, R. A. Hoffman, K. Izuishi, N. D. Critchlow, A. Nakao,
M. H. Chan, M. T. Lotze, D. A. Geller, and T. R. Billiar. Hepatic
ischemia/reperfusion injury involves functional TLR4 signaling
in nonparenchymal cells. J. Immunol. 175:7661–7668 (2005).
41. A. Shimamoto, A. J. Chong, M. Yada, S. Shomura, H. Takayama,
A. J. Fleisig, M. L. Agnew, C. R. Hampton, C. L. Rothnie, D. J.
Spring, T. H. Pohlman, H. Shimpo, and E. D. Verrier. Inhibition of
Toll-like receptor 4 with eritoran attenuates myocardial ischemia-
reperfusion injury. Circulation. 114:I270–4 (2006).
42. J. S. Park, F. Gamboni-Robertson, Q. He, D. Svetkauskaite, J. Y.
Kim, D. Strassheim, J. W. Sohn, S. Yamada, I. Maruyama, A.
Banerjee, A. Ishizaka, and E. Abraham. High mobility group
box 1 protein interacts with multiple Toll-like receptors. Am. J.
Physiol. Cell. Physiol. 290:C917–C924 (2006).
43. D. J. Kaczorowski, A. Nakao, K. P. Mollen, R. Vallabhaneni, R.
Sugimoto, J. Kohmoto, K. Tobita, B. S. Zuckerbraun, K. R.
McCurry, N. Murase, and T. R. Billiar. Toll-like receptor 4
mediates the early inflammatory response after cold ischemia/
reperfusion. Transplantation. 84:1279–1287 (2007).
44. F. Hua, T. Ha, J. Ma, Y. Li, J. Kelley, X. Gao, I. W. Browder, R.
L. Kao, D. L. Williams, and C. Li. Protection against myocardial
ischemia/reperfusion injury in TLR4-deficient mice is mediated
through a phosphoinositide 3-kinase-dependent mechanism. J.
Immunol. 178:7317–7324 (2007).
45. H. J. Anders, B. Banas, and D. Schlondorff. Signaling danger: toll-
like receptors and their potential roles in kidney disease. J. Am.
Soc. Nephrol. 15:854–867 (2004).
46. C. Y. Lu, J. Hartono, M. Senitko, and J. Chen. The inflammatory
response to ischemic acute kidney injury: a result of the ‘right
stuff’ in the ‘wrong place’? Curr. Opin. Nephrol. Hypertens.
16:83–89 (2007).
47. M. Yu, D. Shao, J. Liu, J. Zhu, Z. Zhang, and J. Xu. Effects of
ketamine on levels of cytokines, NF-kappaB and TLRs in rat
intestine during CLP-induced sepsis. Int. Immunopharmacol.
7:1076–1082 (2007).
48. R. K. Weersma, H. M. van Dullemen, G. van der Steege, I. M.
Nolte, J. H. Kleibeuker, and G. Dijkstra. Review article:
Inflammatory bowel disease and genetics. Aliment. Pharmacol.
Ther. 26(Suppl 2):57–65 (2007).
49. P. L. De Jager, D. Franchimont, A. Waliszewska, A. Bitton, A.
Cohen, D. Langelier, J. Belaiche, S. Vermeire, L. Farwell, A.
Goris, C. Libioulle, N. Jani, T. Dassopoulos, G. P. Bromfield, B.
Dubois, J. H. Cho, S. R. Brant, R. H. Duerr, H. Yang, J. I.
Rotter, M. S. Silverberg, A. H. Steinhart, M. J. Daly, D. K.
Podolsky, E. Louis, D. A. Hafler, and J. D. Rioux. The role of
the Toll receptor pathway in susceptibility to inflammatory bowel
diseases. Genes Immun. 8:387–397 (2007).
50. A. Araki, T. Kanai, T. Ishikura, S. Makita, K. Uraushihara, R.
Iiyama, T. Totsuka, K. Takeda, S. Akira, and M. Watanabe.
MyD88-deficient mice develop severe intestinal inflammation in
dextran sodium sulfate colitis. J. Gastroenterol. 40:16–23 (2005).
51. M. M. Fort, A. Mozaffarian, A. G. Stover, S. Correia Jda, D. A.
Johnson, R. T. Crane, R. J. Ulevitch, D. H. Persing, H. Bielefeldt-
Ohmann, P. Probst, E. Jeffery, S. P. Fling, and R. M. Hershberg. A
synthetic TLR4 antagonist has anti-inflammatory effects in two
murine models of inflammatory bowel disease. J. Immunol.
174:6416–6423 (2005).
52. G. Baumgarten, P. Knuefermann, H. Wrigge, C. Putensen, H.
Stapel, K. Fink, R. Meyer, A. Hoeft, and C. Grohe. Role of Toll-
like receptor 4 for the pathogenesis of acute lung injury in Gram-
negative sepsis. Eur. J. Anaesthesiol. 23:1041–1048 (2006).
53. J. Qu, J. Zhang, J. Pan, L. He, Z. Ou, X. Zhang, and X. Chen.
Endotoxin tlerance inhibits lipopolysaccharide-initiated acute
pulmonary inflammation and lung injury in rats by the mecha-
nism of nuclear factor-kappaB. Scand. J. Immunol. 58:613–619
(2003).
54. D. A. Johnson. Synthetic TLR4-active Glycolipids as Vaccine
Adjuvants and Stand-alone Immunotherapeutics. Curr. Top.
Med. Chem. 8:64–79 (2008).
55. D. A. Johnson, C. G. Sowell, C. L. Johnson, M. T. Livesay, D. S.
Keegan, M. J. Rhodes, J. T. Ulrich, J. R. Ward, J. L. Cantrell,
and V. G. Brookshire. Synthesis and biological evaluation of a
new class of vaccine adjuvants: aminoalkyl glucosaminide 4-
phosphates (AGPs). Bioorg. Med. Chem. Lett. 9:2273–2278
(1999).
56. W. J. Christ, O. Asano, A. L. Robidoux, M. Perez, Y. Wang, G. R.
Dubuc, W. E. Gavin, L. D. Hawkins, P. D. McGuinness, and M. A.
Mullarkey. E5531, a pure endotoxin antagonist of high potency.
Science. 268:80–83 (1995).
57. H. M. Kim, B. S. Park, J. I. Kim, S. E. Kim, J. Lee, S. C. Oh, P.
Enkhbayar, N. Matsushima, H. Lee, O. J. Yoo, and J. O. Lee.
Crystal structure of the TLR4-MD-2 complex with bound
endotoxin antagonist Eritoran. Cell. 130:906–917 (2007).
58. T. Kawata, J. R. Bristol, J. R. Rose, D. P. Rossignol, W. J. Christ,
O. Asano, G. R. Dubuc, W. E. Gavin, L. D. Hawkins, and Y.
Kishi. Anti-endotoxin activity of a novel synthetic lipid A analog.
Prog. Clin. Biol. Res. 392:499–509 (1995).
59. K. M. Wasan, F. W. Strobel, S. C. Parrott, M. Lynn, W. J. Christ,
L. D. Hawkins, and D. P. Rossignol. Lipoprotein distribution of a
novel endotoxin antagonist, E5531, in plasma from human
subjects with various lipid levels. Antimicrob. Agents Chemother.
43:2562–2564 (1999).
60. J. R. Rose, M. A. Mullarkey, W. J. Christ, L. D. Hawkins, M.
Lynn, Y. Kishi, K. M. Wasan, K. Peteherych, and D. P. Rossignol.
Consequences of interaction of a lipophilic endotoxin antagonist
with plasma lipoproteins. Antimicrob. Agents Chemother. 44:504–
510 (2000).
61. M. Mullarkey, J. R. Rose, J. Bristol, T. Kawata, A. Kimura, S.
Kobayashi, M. Przetak, J. Chow, F. Gusovsky, W. J. Christ, and D.
P. Rossignol. Inhibition of endotoxin response by e5564, a novel
Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol.
Exp. Ther. 304:1093–1102 (2003).
62. E. Lien, J. C. Chow, L. D. Hawkins, P. D. McGuinness, K.
Miyake, T. Espevik, F. Gusovsky, and D. T. Golenbock. A novel
synthetic acyclic lipid A-like agonist activates cells via the
lipopolysaccharide/toll-like receptor 4 signaling pathway. J. Biol.
Chem. 276:1873–1880 (2001).
63. H. Methe et al. Statins decrease toll-like receptor 4 expression
and downstream signaling in human CD14 monocytes. Arterios-
cler. Thromb. Vasc. Biol. 25:1439 (2005).
64. K. M. Wasan, O. Sivak, R. A. Cote, A. I. MacInnes, K. D.
Boulanger, M. Lynn, W. J. Christ, L. D. Hawkins, and D. P.
Rossignol. Association of the endotoxin antagonist E5564 with
high-density lipoproteins in vitro: dependence on low-density and
triglyceride-rich lipoprotein concentrations. Antimicrob. Agents
Chemother. 47:2796–2803 (2003).
65. S. M. Opal, P. J. Scannon, J. L. Vincent, M. White, S. F. Carroll,
J. E. Palardy, N. A. Parejo, J. P. Pribble, and J. H. Lemke.
Relationship between plasma levels of lipopolysaccharide (LPS)
and LPS-binding protein in patients with severe sepsis and septic
shock. J. Infect. Dis. 180:1584–1589 (1999).
66. M. Lynn, D. P. Rossignol, J. L. Wheeler, R. J. Kao, C. A.
Pardomo, R. Noveck, R. Vargas, T. D’Angelo, S. Gotzkowsky, and
F. G. McMahon. Blocking of responses to endotoxin by E5564 in
healthy volunteers with experimental endotoxemia. J. Infect. Dis.
187:631–639 (2003).
67. D. P. Rossignol, K. M. Wasan, E. Choo, E. Yau, N. Wong, J.
Rose, J. Moran, and M. Lynn. Safety, pharmacokinetics,
pharmacodynamics, and plasma lipoprotein distribution of
eritoran (E5564) during continuous intravenous infusion into
1760 Leon et al.
healthy volunteers. Antimicrob. Agents Chemother. 48:3233–3240
(2004).
68. M. Ii et al. A novel cyclohexene derivative, ethyl (6 R)-6-[N-(2-
chloro-4-fluorophenyl) sulfamoyl] cyclohex-1-ene-1-carboxylate
(TAK-242), selectively inhibits toll-like receptor 4-mediated cyto-
kine production through suppression of intracellular signaling.Mol.
Pharmacol. 69:1288 (2006).
69. T. Sha, M. Sunamoto, T. Kitazaki, J. Sato, M. Ii, and Y. Iizawa.
Therapeutic effects of TAK-242, a novel selective Toll-like
receptor 4 signal transduction inhibitor, in mouse endotoxin
shock model. Eur. J. Pharmacol. 571:231–239 (2007).
70. T. Kawamoto, M. Ii, T. Kitazaki, Y. Iizawa, and H. Kimura.
TAK-242 selectively suppresses Toll-like receptor 4-signaling
mediated by the intracellular domain. Eur. J. Pharmacol. 584
(1):40–8 (2008).
71. D. C. Angus, and R. S. Wax. Epidemiology of sepsis: an update.
Crit. Care Med. 29:S109–S116 (2001).
72. R. S. Hotchkiss, and I. E. Karl. The Pathophysiology and
Treatment of Sepsis. N. Engl. J. Med. 348:138 (2003).
73. G. Bernard. Drotrecogin alfa (activated) (recombinant human
activated protein C) for the treatment of severe sepsis. Crit. Care
Med. 31:85–93 (2003).
74. Y. N. Wong, D. Rossignol, J. R. Rose, R. Kao, A. Carter, and M.
Lynn. Safety, pharmacokinetics, and pharmacodynamics of E5564,
a lipid A antagonist, during an ascending single-dose clinical study.
J. Clin. Pharmacol. 43:735–742 (2003).
75. E. Bennett-Guerrero. A phase II, double-blind, placebo-controlled,
ascending-dose study of Eritoran (E5564), a lipid A antagonist, in
patients undergoing cardiac surgery with cardiopulmonary bypass.
Anesth. Analg. 104:378 (2007).
76. K. Kaneko, R. Ueda, T. Kawata, S. Ishizaka, and T. Yoshimura.
LPS binding protein does not participate in the pharmacokinetics
of E5564. J. Endotoxin Res. 10:185 (2004).
77. E. Czeslick, A. Struppert, A. Simm, and A. Sablotzki. E5564
(Eritoran) inhibits lipopolysaccharide-induced cytokine produc-
tion in human blood monocytes. Inflamm. Res. 55:511 (2006).
78. K. J. Ishii, S. Uematsu, and S. Akira. ‘Toll’ gates for future
immunotherapy. Curr. Pharm. Des. 12:4135–4142 (2006).
1761Discovery and Development of TLR4 Antagonists
